Core Viewpoint - The article discusses the recent A-round financing of Zhiruan Medical, highlighting its focus on invasive brain-computer interface (BCI) technology and the advancements in flexible electrode development [7][9]. Company Overview - Zhiruan Medical has completed over 300 million yuan in A-round financing, with total funding since its establishment in 2022 nearing 500 million yuan [7][8]. - The company was co-founded by Dr. Fang Ying and Dr. Song Qi, both of whom have extensive backgrounds in neuroscience and AI medical technology [8]. Technology and Innovation - Zhiruan Medical specializes in invasive BCI technology, which allows for high-resolution neural signal collection and precise neuron modulation through implanted electrodes [9]. - The company has developed a high-throughput flexible electrode that has received patent authorization in both China and the U.S., achieving high efficiency in neuron signal collection [9][10]. - A fully implanted wireless signal acquisition system has been created, capable of collecting action potentials from up to 1024 channels, with a significant reduction in power consumption [10]. Research and Development - The company has established a high-precision brain data platform with over 20TB of animal neuron data and 6TB of human deep brain region data, enhancing model training speed and decoding performance [10]. - Zhiruan Medical has also developed a multi-degree-of-freedom implantation robot to improve the efficiency and safety of electrode implantation [10]. Industry Context - The global BCI industry is entering a rapid development phase, with companies like Neuralink making progress in human clinical trials [11]. - The shift from rigid to flexible electrodes is seen as crucial for improving signal quality and stability, which is essential for clinical applications [11]. - Invasive BCI technology holds potential for breakthroughs in treating conditions such as spinal cord injuries, ALS, and depression [11].

Core Viewpoint - The article discusses the recent A-round financing of Zhiruan Medical, highlighting its focus on developing next-generation technologies and conducting large-scale clinical trials [3][4]. Financing and Company Background - Zhiruan Medical has completed over 300 million yuan in A-round financing, led by various investors including social security funds and venture capital firms [3]. - Since its establishment in 2022, the company has raised nearly 500 million yuan in total financing [4]. - The company was co-founded by Dr. Fang Ying and Dr. Song Qi, both of whom have extensive backgrounds in neuroscience and AI medical technology [4]. Technology and Innovation - Zhiruan Medical specializes in invasive brain-computer interface (BCI) technology, which allows for high-resolution neural signal collection and precise neuron modulation [5]. - The company has developed proprietary high-throughput flexible electrodes that have received patent authorization in both China and the U.S., enabling efficient neural signal collection [5][6]. - A fully implanted high-throughput wireless signal acquisition system has been created, capable of collecting neural action potentials from up to 1024 channels [6]. Research and Development - The company has built a high-precision brain data platform with over 20TB of animal neural data and 6TB of human deep brain data to enhance model training and decoding performance [6]. - Zhiruan Medical has also developed a multi-degree-of-freedom implantation robot to improve the efficiency and safety of electrode implantation [6]. Industry Context - The global BCI industry is entering a rapid growth phase, with companies like Neuralink making significant advancements in human clinical trials [7]. - The shift from rigid to flexible electrodes is seen as crucial for improving signal quality and reducing immune response risks, which are key factors for clinical application [7]. - Invasive BCI technology is expected to make breakthroughs in treating conditions such as spinal cord injuries, ALS, and depression [7].

Group 1 - The core viewpoint of the article highlights the significant funding round completed by Zhiran Medical, raising over 300 million yuan, bringing the total financing to nearly 500 million yuan since its establishment in 2022 [2] - The funding will primarily be used for core technology research and large-scale clinical trials, indicating a strong focus on advancing their invasive brain-machine interface technology [2][8] - Zhiran Medical's approach aligns with high-difficulty invasive solutions, utilizing ultra-thin flexible electrodes, which are considered crucial for efficient human-machine interaction [3][5] Group 2 - The company has developed a high-throughput flexible electrode that has received patent authorization in China and the U.S., designed to minimize implantation damage and enhance long-term signal stability [5][7] - A fully implanted high-throughput wireless signal acquisition system has been self-developed, capable of collecting action potentials from 1024 channels, which is complemented by deep neural network algorithms for precise intent decoding [7] - The establishment of a clinical-grade micro-nano processing workshop and GMP workshop allows for a fully controllable process from research and design to mass production, ensuring industrialization for future medical applications [7] Group 3 - The investment community views the invasive brain-machine interface as transitioning from laboratory research to clinical application, with breakthroughs in core technology and systematic implementation being key competitive indicators [8] - The Chinese government has issued policies encouraging the development of high-performance brain signal sensing components and surgical robots, providing a supportive environment for industry growth [8] - The combined effect of technology, capital, and policy is accelerating the clinical and industrialization processes of invasive brain-machine interfaces, making the performance of Zhiran Medical and similar companies a focal point for ongoing observation [8]